Fed. Circ. Backs PTAB's Invalidation Of J&J Remicade Patent
The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating a Johnson & Johnson patent on the blockbuster autoimmune disease drug Remicade for double patenting, in a...To view the full article, register now.
Already a subscriber? Click here to view full article